Hester Biosciences Valuation

Q: What is the Fair Price of HESTERBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

HESTERBIO (₹2385.45) is trading above our estimate of [[fair value]] (₹106.26)

Is HESTERBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HESTERBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HESTERBIO (₹2385.45) is trading above our estimate of fair value (₹106.26)

Significantly Below Fair Value: HESTERBIO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HESTERBIO?

Key metric: As HESTERBIO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HESTERBIO. This is calculated by dividing HESTERBIO's market cap by their current earnings.
What is HESTERBIO's PE Ratio?
PE Ratio	86.2x
Earnings	₹234.69m
Market Cap	₹20.24b

HESTERBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.2x
Enterprise Value/EBITDA	33.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does HESTERBIO's PE Ratio compare to its peers?

The above table shows the PE ratio for HESTERBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	41.6x
532039 Zenotech Laboratories	70.2x	n/a	₹4.7b
NIRMAN Nirman Agri Genetics	13.1x	n/a	₹2.4b
BIOCON Biocon	27.6x	6.8%	₹396.7b
524470 Syncom Formulations (India)	55.3x	n/a	₹18.3b
HESTERBIO Hester Biosciences	86.2x	n/a	₹20.2b

Price-To-Earnings vs Peers: HESTERBIO is expensive based on its Price-To-Earnings Ratio (86.2x) compared to the peer average (41.6x).

Price to Earnings Ratio vs Industry

How does HESTERBIO's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: HESTERBIO is expensive based on its Price-To-Earnings Ratio (86.2x) compared to the Asian Biotechs industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is HESTERBIO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HESTERBIO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	86.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HESTERBIO's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹293.6m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹21.05

7.4%

-0.9%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹291.85

-3.6%

-22.2%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

-1.7%

15.6%